medigraphic.com
ISSN 2448-8909 (Print)

2022, Number 3

<< Back Next >>

Med Crit 2022; 36 (3)

Delta uric acid as a predicator of severity in patients with SARS-CoV-2

Pérez FO, Mendoza PE, Mendoza RM

Language: Spanish
References: 18
Page: 142-147
PDF size: 178.27 Kb.


ABSTRACT

Introduction: SARS-CoV-2 represents the first cause of current mortality in the Mexican population, globally it has accumulated 1'919,126 deaths. The regions with the most deaths are America (47%), Europe (33%). Until week two of 2021 in Mexico, 1'541,633 cases were estimated, with Mexico City being the most affected entity, until that moment 18,443 deaths had been registered, with a hospital need of 80%, and with a high demand for hospitalization in the service of Intensive Care Unit (ICU). For this reason, the need arises for new early markers of severity and prognosis. Objective: To correlate the uric acid delta (DAU) with mortality in patients with SARS-CoV-2 treated in the ICU, as well as its relationship with other variables of severity. Material and methods: A longitudinal study was carried out in the ICU with 71 patients and study variables: demographic, comorbidities, days of ICU stay, days of mechanical ventilation (MV), predictive mortality scale, initial uric acid and final uric acid, DAU; outcome: mortality. Results: Of the participants, 69% were men, 31% women, mean age of 54.35 years (± 10.28), uric acid at admission of 3.9 mg/dL (± 1.74), uric acid at discharge of 2.89 mg/dL (± 1.70), mean uric acid delta of 1.077 mg/dL (± 1.59 mg/dL), APACHE II at entry of 18.35 points (± 9.04) at discharge of 22.95 points (± 19.68), global mortality of 50.7%, of which 78.67% required mechanical ventilation (MV) and 21.12% did not require. The Spearman correlation for DAU and mortality was r = -0.34, the determination index r2 = 0.13, with significance p = 0.004, (CI) 95%. Conclusions: The correlation between the DAU with the mortality of the patients with SARS-CoV-2 was demonstrated with adequate statistical significance at a cut-off interval of 1-1.5 mg/dL, and a mortality of 50.7%. Additionally, it was shown that said interval had a correlation with the start of mechanical ventilation. It was identified that if there is a relationship between the APACHE II score and SARS-CoV-2 mortality, for this study a score greater than 18 demonstrated the best statistical significance.


REFERENCES

  1. Secretaria de Salud. 2o Informe epidemiológico de la situación de Covid-19. Dirección de información epidemiológica. México. 2021.

  2. Peralta-Prado AB, Ramírez-Hinojosa JP, Ramírez-Polo AI, López-Aguilar CE, Maya-Romero H, Carrillo-Esper R. Correlación de la delta de ácido úrico con la gravedad de la sepsis. Med Int Mex. 2016;29:154-158.

  3. Aminiahidashti H, Bozorgi F, Mousavi SJ, Sedighi O, Gorji AM, Rashidian H. Serum uric acid level in relation to severity of the disease and mortality of critically ill patients. J Lab Physicians. 2017;9(1):42-46.

  4. Bhandary NM, Shetty IJ, Akshatha H. Hyperuricemia as an early marker in predicting the mortality and morbidity in patients with sepsis. Int J Contemp Med Res. 2019;6(3): 2393-2915.

  5. Suárez V, Suarez Quezada M, Oros Ruiza S, Ronquillo De Jesús E. Epidemiología de COVID-19 en México: del 27 de febrero al 30 de abril de 2020. Rev Clin Esp. 2020;220(8):463-471.

  6. Chen Q, Huang K, Li L, Lin X, Ding C, Zhang J, Chen Q. Serum uric acid on admission cannot predict long-term outcome of critically ill patients: a retrospective cohort study. Ther Clin Risk Manag. 2018;14:1347-1359.

  7. Giovannini I, Chiarla C, Giuliante F, Pallavicini F, Vellone M, Ardito F, et al. Serum uric acid, creatinine, and the assessment of antioxidant capacity in critical illness. Crit Care. 2006;10(5):421.

  8. Gao L, Shi Q, Li H, Guo Q, Yan J. Prognostic value of baseline APACHE II score combined with uric acid concentration for short-term clinical outcomes in patients with sepsis. All Life. 2020;13(1):416-425.

  9. Pehlivanlar-Kucuk M, Kucuk AO, Ozturk CE, Er MC, Ulger F. The association between serum uric acid level and prognosis in critically ill patients, uric acid as a prognosis predictor. Clin Lab. 2018;64(9):1491-1500.

  10. Akbar SR, Long DM, Hussain K, Alhajhusain A, Ahmed US, Iqbal HI, et al. Hyperuricemia: an early marker for severity of illness in sepsis. Int J Nephrol. 2015;2015:301021.

  11. Hussain Bhat A. Uric acid a predictor of sepsis in critically ill patients. J Adv Med Dental Sci Res. 2018;6(1):158-161.

  12. Zhu HC, Cao RL. The relationship between serum levels of uric acid and prognosis of infection in critically ill patients. World J Emerg Med. 2012;3(3):186-190.

  13. Kuipers MT, Aslami H, Van der Poll T, Schultz M, Wieland C. Danger signal uric acid is involved in ventilator-induced lung injury pathogenesis. Crit Care. 2011;15(suppl 1):P192.

  14. Elshafey M, Abu Mossalam AM, Makharita MY, Elewa A. Prognostic role of serum uric acid in acute respiratory distress syndrome patients: a preliminary study. Egypt J Chest Dis Tuberc. 2015;64(1):197-202.

  15. Kuipers MT, Aslami H, Vlaar AP, Juffermans NP, Tuip-de Boer AM, Hegeman MA, et al. Pre-treatment with allopurinol or uricase attenuates barrier dysfunction but not inflammation during murine ventilator-induced lung injury. PLoS One. 2012;7(11):e50559.

  16. Ghiselli A, Serafini M, Natella F, Capacidad antioxidante total como herramienta para evaluar el estado redox: vista crítica y datos experimentales. Free Rad Biol Med. 2016;29:1106-1111.

  17. Alcántara-Alonso E, Molinar-Ramos F, González-López JA, Alcántara-Alonso V, Muñoz-Pérez MA, Lozano-Nuevo JJ, et al. High triglyceride to HDL-cholesterol ratio as a biochemical marker of severe outcomes in COVID-19 patients. Clin Nutr ESPEN. 2021;44:437-444.

  18. Dufour I, Werion A, Belkhir L, Wisniewska A, Perrot M, De Greef J, et al. Serum uric acid, disease severity and outcomes in COVID-19. Crit Care. 2021;25(1):212.




2020     |     www.medigraphic.com